Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer.
作者信息
Liang Wenhua, Cai Kaican, Chen Chun, Chen Haiquan, Chen Qixun, Fu Junke, Hu Jian, Jiang Tao, Jiao Wenjie, Li Shuben, Liu Changhong, Liu Deruo, Liu Wei, Liu Yang, Ma Haitao, Pan Xiaojie, Qiao Guibin, Tian Hui, Wei Li, Zhang Yi, Zhao Song, Zhao Xiaojing, Zhou Chengzhi, Zhu Yuming, Zhong Ran, Li Feng, Rosell Rafael, Provencio Mariano, Massarelli Erminia, Antonoff Mara B, Hida Toyoaki, de Perrot Marc, Lin Steven H, Di Maio Massimo, Rossi Antonio, De Ruysscher Dirk, Ramirez Robert A, Dempke Wolfram C M, Camidge D Ross, Guibert Nicolas, Califano Raffaele, Wang Qi, Ren Shengxiang, Zhou Caicun, He Jianxing
机构信息
Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Nanfang Hospital, Guangzhou, China.
出版信息
Transl Lung Cancer Res. 2020 Dec;9(6):2696-2715. doi: 10.21037/tlcr-2020-63.
Abstract
摘要
相似文献
1
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer.
Transl Lung Cancer Res. 2020 Dec;9(6):2696-2715. doi: 10.21037/tlcr-2020-63.
2
The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer.
J Thorac Cardiovasc Surg. 2023 Sep;166(3):637-654. doi: 10.1016/j.jtcvs.2023.04.039. Epub 2023 Jun 10.
3
[Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].
Zhongguo Fei Ai Za Zhi. 2024 Feb 20;27(2):138-146. doi: 10.3779/j.issn.1009-3419.2024.102.06.
4
[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2022 edition)].
Zhonghua Zhong Liu Za Zhi. 2022 Oct 23;44(10):1047-1065. doi: 10.3760/cma.j.cn112152-20220614-00416.
5
[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)].
Zhonghua Zhong Liu Za Zhi. 2023 Sep 23;45(9):717-740. doi: 10.3760/cma.j.cn112152-20230420-00179.
6
Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
Thorac Cancer. 2021 Oct;12(20):2796-2802. doi: 10.1111/1759-7714.14127. Epub 2021 Aug 30.
7
[Progress of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer].
Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):524-533. doi: 10.3779/j.issn.1009-3419.2022.101.29.
8
Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology.
Eur Radiol. 2023 Oct;33(10):6625-6635. doi: 10.1007/s00330-023-09922-4. Epub 2023 Jul 29.
9
[Chinese Experts Consensus on Immune Checkpoint Inhibitors
for Non-small Cell Lung Cancer (2020 Version)].
Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):217-235. doi: 10.3779/j.issn.1009-3419.2021.101.13. Epub 2021 Apr 26.
10
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP.
Clin Transl Oncol. 2024 Jul;26(7):1647-1663. doi: 10.1007/s12094-024-03382-y. Epub 2024 Mar 26.
引用本文的文献
1
Sirtuin family in lung adenocarcinoma.
Discov Oncol. 2025 Jul 23;16(1):1398. doi: 10.1007/s12672-025-03217-4.
2
Prognostic factors for non-small cell lung cancer after neoadjuvant therapy and surgery: a retrospective observational study.
J Thorac Dis. 2025 May 30;17(5):2841-2855. doi: 10.21037/jtd-2024-1651. Epub 2025 May 27.
3
Quantitative F-FDG PET/CT Model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST.
Eur J Nucl Med Mol Imaging. 2025 May 26. doi: 10.1007/s00259-025-07342-8.
4
Analysis of the safety and feasibility of sleeve resection under UniVATS after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancer.
World J Surg Oncol. 2025 Mar 14;23(1):85. doi: 10.1186/s12957-024-03462-x.
5
Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial.
Nat Cancer. 2025 Mar;6(3):432-444. doi: 10.1038/s43018-025-00922-5. Epub 2025 Feb 27.
6
Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies.
Ther Adv Med Oncol. 2025 Jan 8;17:17588359241312501. doi: 10.1177/17588359241312501. eCollection 2025.
7
Advances in molecular imaging and targeted therapeutics for lymph node metastasis in cancer: a comprehensive review.
J Nanobiotechnology. 2024 Dec 19;22(1):783. doi: 10.1186/s12951-024-02940-4.
8
Major pathologic response predicts survival in resectable stage IIIA non-small cell lung cancer after neoadjuvant therapy.
Interdiscip Cardiovasc Thorac Surg. 2024 Dec 25;40(1). doi: 10.1093/icvts/ivae213.
9
Neoadjuvant immunology therapy in patients with non-small cell lung cancer and chronic obstructive pulmonary disease.
J Thorac Dis. 2024 Nov 30;16(11):7546-7560. doi: 10.21037/jtd-24-811. Epub 2024 Nov 8.
10
Lung autotransplantation for advanced central lung cancer after neoadjuvant immuno-chemotherapy: a case series study.
Transl Lung Cancer Res. 2024 Nov 30;13(11):2868-2879. doi: 10.21037/tlcr-24-501. Epub 2024 Nov 18.
本文引用的文献
1
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).
J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2022-005636.
2
Two Patients With Advanced-Stage Lung Adenocarcinoma With Radiologic Complete Response to Nivolumab Treatment Harboring an / Mutation.
JCO Precis Oncol. 2020 Nov;4:1239-1245. doi: 10.1200/PO.20.00174.
3
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2020 Nov;21(11):1413-1422. doi: 10.1016/S1470-2045(20)30453-8. Epub 2020 Sep 24.
4
Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
J Thorac Oncol. 2020 Aug;15(8):1281-1297. doi: 10.1016/j.jtho.2020.05.020. Epub 2020 Jun 6.
5
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies.
Cancers (Basel). 2020 Jun 5;12(6):1475. doi: 10.3390/cancers12061475.
6
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2020 Jun;21(6):786-795. doi: 10.1016/S1470-2045(20)30140-6. Epub 2020 May 7.
7
Tumor-Associated Macrophages: Recent Insights and Therapies.
Front Oncol. 2020 Feb 25;10:188. doi: 10.3389/fonc.2020.00188. eCollection 2020.
8
NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors.
Cancer Res. 2020 May 1;80(9):1846-1860. doi: 10.1158/0008-5472.CAN-19-3158. Epub 2020 Mar 2.
9
The efficiency of F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1209-1219. doi: 10.1007/s00259-020-04711-3. Epub 2020 Feb 11.
10
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.
J Thorac Oncol. 2020 May;15(5):816-826. doi: 10.1016/j.jtho.2020.01.017. Epub 2020 Feb 6.
Zotero 插件